Introduction of a radioactive gastrointestinal marker (5"CrC13) into a combined study ('5SeHCAT+58CoBl2) of ileal function by whole body counting has been undertaken. The technique was assessed in 23 subjects (15 patients with inflammatory bowel disease, six on non-steroidal anti-inflammatory drugs for rheumatoid arthritis, and two normal subjects). Mean (SD) 51CrC13 retention was only 4-1 (6.0)% on day 4, and was similar on day 7 in subjects given a second dose of "CrCl3 on day 4. Only one subject had more than 20% of 51CrC13 retention after four days. A 5"CrC13 correction method adequately corrected for colonic hold up of 5'CoB12, when compared with final equilibrium values of wCoBl2 retention. Use of the non-absorbed 58CoB12 fraction as a gastrointestinal marker gave good agreement with the 51CrCl3 method in correcting 75SeHCAT values. In all subjects studied, corrections for colonic retention of 71SeHCAT on day 4, were small (<7% of dose) and did not affect the assessment of any subject. In conclusion, an additional gastrointestinal marker such as 51CrCl3 is unnecessary in our combined study since that role can be effected, when indicated, by the non-absorbed 58CoB12 fraction.
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Vitamin B12 is also absorbed predominantly at the terminal ileum, but by a different mechanism to that for SeHCAT, and the combined use of radiolabelled B12 and SeHCAT has been successfully exploited by whole body counting.'6'0 In our combined study of 75SeHCAT and "8CoB12, 6 it was suggested that analysis of the relative patterns of retention of the two test substances could be used to check for evidence of colonic retention. It was considered prudent, however, to attempt to apply the I'CrC13 gastrointestinal marker technique in our whole body counting protocol to substantiate this claim and furthermore to assess and quantify the influence of colonic retention on the overall results. We therefore incorporated "CrCl3, administered orally and together with 75SeHCAT and '8CoB12 (plus intrinsic factor), in our combined test of ileal function'6 to assess the efficiency of colonic emptying on three study days (days 4, 7, and 10), and to consider the prospects for correcting the "SeHCAT and '8CoB12, retention values in patients with inflammatory bowel disease and non-steroidal anti-inflammatory drug enteropathy. Sections Considering the combined use of 75Se (0-124-40 MeV), 5'Cr (0-32 MeV), and 58Co (0-51, 0-81 MeV) in individual subjects, it was necessary to obtain estimates of spectral crossover factors for "Co in the 5Cr and 75Se channels, for 5'Cr in the 75Se channel, and also for 75Se in the 5'Cr channel because of overlap of the channels selected for 5'Cr and 75Se (Fig 1) . Crossover of one radionuclide (A) with another (B) is defined as the ratio (net counts/second in channel B)/(net counts/second in channel A).
(a) Crossover of 58Co into 5Cr and 75Se channels. These data were obtained retrospectively from whole body measurements on 15 patients who had undergone diagnostic assessment of B12 absorption using 58CoB12 alone. Crossover factors were obtained at between five and 14 days after 58CoB12 administration and, additionally, crossover into the 5Cr channel was measured at one hour. Crossover factors were plotted against body weight, and linear regression lines together with 95% confidence limits about regression were calculated.
(b) Crossover of 5Cr into 75Se channel. Data were obtained retrospectively from whole body counting studies on seven subjects given oral 5'Cr ethylenediamenetetra acetic acid for investigation of intestinal permeability. 9 For each subject the average crossover factor obtained from three to four measurements over two days was calculated and plotted against body weight. As above, linear regression and 95% confidence limits were calculated.
(c) Crossover of 15Se into 5'Cr channel. Data were obtained individually for subjects in the present study, one hour after oral administration of 75SeHCAT. In view of the fact that "8CoB 12 and 5CrCl3 were administered immediately after this measurement, later observations of this crossover could not be made and consequently the one hour crossover served for analysis of measurements made at all times. Tests were conducted to establish that this was a sufficiently accurate procedure.
CALCULATIONS
Crossover factors (a) and (b) above were interpolated from curves using the subject's weight. Count rates, net of background, in the 75Se and 5Cr channels were corrected firstly for crossover of the "Co spectrum. The corrected counts were then used in simultaneous equations, incorporating the respective crossover factors for these two channels, to obtain count rates due to 75SeHCAT and 5'CrCl3 alone. These, together with the net count rate in the 58Co channel, were decay corrected to day 0 and expressed as a percentage of the appropriate 100% (one hour) count rates. In all cases, 95% confidence limits on these values, resulting from the uncertainty in crossover corrections, were also calculated.
Results

CROSSOVER OF GAMMA-RAY SPECTRA
The crossover data are shown in Figure 2 plotted against body weight. Best fitting straight lines were calculated and used to interpolate appropriate crossover factors for subjects in the present study. The average 95% confidence limits on these crossover factors were +8 Yo and +7.5% for 58Co in the 5Cr channel at early (one hour) and later (five to 14 days) times respectively; ±2-7% for "Co in the 75Se channel; and +5-9% for 5Cr in the 75Se channel. The effects of these limits on measured and corrected 75SeHCAT retention values are shown later. Only the crossover of 75Se in the 5Cr channel was obtained directly in the present studies, as measured one Body weight (kg) hour after administration of 75SeHCAT. The validity of using this and other crossover factors was examined in seven patients from previous studies who were given "SeHCAT and "8CoB12 without 5"CrC13: using crossovers as described above, the residual whole body counts estimated in the 5"Cr channel at four and seven days were equivalent, on average, to less than 0-5% of the mean 5'CrCl3 activity administered in the present studies.
WHOLE-BODY RETENTION OF 51CrC13
In all 23 subjects, the average whole body retention on day 4 was 4 1 mean (SD) (6-0)% of the first administration of oral 5CrCl3 and exceeded 5% in only five. Seventeen subjects, who were given a second 5"CrCl3 administration on day 4, showed average retention of the first administration, 4-8 (6 6)% (day 4) and, of the second administration, 4-4 (6-8)% (day 7) and 0-4 (1-0)% (day 10: n=8). Only one subject, a patient with ileal Crohn's disease, had a 5CrCl3 retention greater than 20% -that is 22-0% of the first administration (day 4) and 28-5% of the second (day 7). Figure 5 vn in Figure 4 , (Fig 3) equivalent to that of '8CoBI2 with highest effective dose equivalents, in a normal -h to compare the corrected values. In view subject given two 5CrCl3 administrations, is he fact that the non-absorbed fraction of 02 mSv. 58CoB12 also acts as an effective gut marker, however, the early 75SeHCAT retention data were additionally corrected using "8CoB 12 retention values by means of the formula: Discussion Our results show that, with appropriate attention to technical details, the use of a "CrCl3 nonabsorbed gastrointestinal marker can be applied successfully in a combined test with "5SeHCAT and "8CoB12 measured by whole body counting. Application of specific crossover corrections for individual subjects is facilitated by the observed relations between crossover and body weight. The accuracy of the crossover factors interpolated from these relations was verified by the finding that net counts in the 5Cr channel were practically zero in patients given both 75SeHCAT and 58CoB12 but no 5CrC13. The 95% confidence limits on all crossover factors have been taken into account in calculating the range of error in individual retention values resulting from the most adverse combination of these errors. In this study, the ranges for retention values on and after day 4 were acceptable, mainly because we found low retention of "CrCl3 at these times. It is clear, however, from considerably larger potential errors are associated with earlier retention measurements. We conclude from these observations that the addition of the "CrCl3 marker has not seriously compromised the estimates of "SeHCAT retention or marker corrected values for days 4, 7, and 10, which was the main objective of this study. Our results suggest, however, that if earlier retention values were required, using the 51CrC13 marker, the details of the present protocol would require modification.
In this study of 23 subjects there was satisfactory gut clearance as indicated by a mean retention of less than 5% of the "CrCl3 marker on day 4, which is the first measurement day in our protocol for the combined "SeHCAT and "CoB 12 test. Figure 6 shows the values of whole body retention of "SeHCAT on day 4, before and after correction by "CrCl3 marker, for all the subjects studied. The normal range was established in a previous study' based on uncorrected data. In the present study, all the 12 subjects whose retention at four days fell within the normal range, had normal retentions at day 7. With only one marginal exception, retention values remained in the normal range after correction by 1'CrCl3. Of the remaining 11 subjects whose retentions on day 4 were subnormal, 10 remained subnormal on day 7. Further evidence of continued gut clearance at later stages in the study was observed in 17 subjects who were given a second administration of "CrCl3 on day 4. Only one measurement showed a raised retention ofmarker greater than 20%, and this was in a patient with Crohn's disease. Six patients with rheumatoid arthritis showed a mean (SD) retention of"CrCl3 at four days of only 4.6 (5 8)%. In our earlier studies,' we found significant reductions in the mean four and seven day retentions of 75SeHCAT by patients with rheumatoid arthritis treated with non-steroidal antiinflammatory drugs compared with normal subjects, but this effect was much less than that seen in patients with Crohn's disease. There was a wide range in retention values for the patients with rheumatoid arthritis but the present results suggest this finding may be due to variable effects of administered drugs on bowel function rather than artefacts resulting from colonic retention. Examination of the patterns of I"CoB12 retention in the earlier studies' also supports this conclusion.
These results show that the use of IICrCl3 gastrointestinal marker administered as a bolus together with "CoB12 corrects for colonic retention of the latter with reasonable accuracy, suggesting that the I'CrCl3 marker and nonabsorbed I"CoB12 are handled in a similar manner by the gastrointestinal tract. Thus since B12 absorption is a non-cycling event, the estimation of non-absorbed I"CoB12 using the "CrCl3 marker, administered simultaneously, accurately predicts the absorbed fraction of "CoB12 (Fig 4) . Similarly, there is no reason to believe that colonic transit of 75SeHCAT differs from that of the IICrCl3 marker. Because 75SeHCAT is constantly recycled in the enterohepatic system, however, its elimination from the gastrointestinal tract is a continuous process, unlike that of Bl2, and an accurate correction for the colonic content of 75SeHCAT cannot be achieved by a single administered bolus of 5'CrCl3. This is illustrated by the whole body retention curve (Fig 3) . The colon is likely to contain 75SeHCAT as long as any remains in the body, and this could only be accurately corrected for by constant infusion of a gastrointestinal marker. Nevertheless, the use of a "CrCl3 bolus does allow a correction based on a 'first pass' of I'CrCl3, as indicated by the plateau in Fig 3 and which can be deduced up until the I'CrCl3 marker is totally eliminated. Whether the application of such a correction in a modified test of "SeHCAT retention by whole body counting would increase the sensitivity of the test is uncertain but our results suggest that a correc- Ferraris et al'4 described a method of abdominal counting of 75SeHCAT by collimated gamma camera in which an administered bolus of 5CrCl3 was used to correct for colonic retention of 75SeHCAT, assuming exponential clearance of both substances. Colonic 75SeHCAT retentions of up to 68% were reported and, after correction, the retention slope of 75SeHCAT was similar to that obtained for the gall bladder region alone. We have not investigated this technique in our studies because, with one exception, we have not seen colonic retentions of such magnitude on days 4, 7, or 10, either in the present studies using 5"CrC13 or in our previous studies as judged from "8CoB 12 retentions. In our previous studies only one patient, who had a psychiatric illness, showed excessive retention; all the administered 75SeHCAT and 58CoB12 being measurable in the body up to 10 days.
Although the measurement of 75SeHCAT retention in the gall bladder, using a collimated gamma camera, provides a method of measuring bile acid turnover free from artefacts due to colonic retention, it has required the administration of 925 kBq of 75Se'4. Abdominal counting by uncollimated gamma camera requires less 75SeHCAT activity (185-370 kBq3 1112) but is unsuitable for this type of multiple radionuclide study, for which whole body counting is the most practical technique. The latter requires only 18-5-37 kBq 75SeHCATI '6 and, although it is subject to errors arising from colonic retention, the results of the present study indicate that colonic retention of 75SeHCAT at seven days is unlikely to be a serious problem, and that in the combined test (75SeHCAT+58CoB12) any hold up would be apparent from the differing patterns of retention ofthe two substances. Moreover, the principal use of 75SeHCAT is in the investigation of diarrhoea, in which colonic hold up is not a feature.
In conclusion, the incorporation of a nonabsorbed gastrointestinal marker such as "CrCl3 into the protocol of a combined test of ileal function using 75SeHCAT and 58CoB 126 is not recommended for the following reasons:
(a) It complicates the test, requiring extra calibration and, in particular, estimates of additional crossover factors which reduce the accuracy of measurement.
(b) A single bolus marker is not ideal for monitoring the continuously emptying pool of SeHCAT.
(c) Any significant colonic hold up of 75SeHCAT would be evident and correctable from the pattern of 58CoB 12 retention.
